Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Human immunodeficiency virus type 1 reverse transcriptase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Trypanosoma brucei | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Plasmodium yoelii | integrase-related | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma congolense | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | N-myristoyltransferase | 0.1168 | 0.3732 | 1 |
Entamoeba histolytica | glycylpeptide N-tetradecanoyltransferase, putative | 0.1168 | 0.3732 | 0.5 |
Trichomonas vaginalis | N-myristoyl transferase, putative | 0.1168 | 0.3732 | 1 |
Leishmania major | N-myristoyl transferase, putative | 0.1168 | 0.3732 | 0.5 |
Plasmodium falciparum | glycylpeptide N-tetradecanoyltransferase | 0.1168 | 0.3732 | 0.5 |
Trypanosoma cruzi | N-myristoyl transferase, putative | 0.1168 | 0.3732 | 0.5 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.308 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.308 | 1 | 1 |
Echinococcus multilocularis | proto oncogene serine:threonine protein kinase | 0.308 | 1 | 1 |
Plasmodium vivax | glycylpeptide N-tetradecanoyltransferase, putative | 0.1168 | 0.3732 | 0.5 |
Onchocerca volvulus | Serine\/threonine protein kinase homolog | 0.308 | 1 | 0.5 |
Trypanosoma brucei | N-myristoyl transferase, putative | 0.1168 | 0.3732 | 1 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.308 | 1 | 1 |
Brugia malayi | Serine/threonine-protein kinase Pim-3 | 0.308 | 1 | 1 |
Echinococcus granulosus | proto oncogene serine:threonine protein kinase | 0.308 | 1 | 1 |
Schistosoma mansoni | N-myristoyltransferase | 0.1168 | 0.3732 | 0.3583 |
Trypanosoma brucei | RNA helicase, putative | 0.01 | 0.0233 | 0.0624 |
Trypanosoma cruzi | N-myristoyl transferase, putative | 0.1168 | 0.3732 | 0.5 |
Giardia lamblia | CDC72 | 0.1168 | 0.3732 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (functional) | = 234 uM | Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. | ChEMBL. | 1732552 |
CC50 (functional) | = 234 uM | Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. | ChEMBL. | 1732552 |
EC50 (functional) | = 10 uM | Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. | ChEMBL. | 1732552 |
EC50 (binding) | = 10 uM | Inhibitory concentration against HIV-1 reverse transcriptase | ChEMBL. | 9435895 |
EC50 (binding) | = 10 uM | Inhibitory concentration against HIV-1 reverse transcriptase | ChEMBL. | 9435895 |
Log 1/C (functional) | = 5 | Tested for 50% protection of MT-4 cells from HIV infection | ChEMBL. | No reference |
Selectivity index (functional) | = 23 | Ratio of EC50/CC50 | ChEMBL. | 1732552 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.